The positive results from the LPCN 1148 Phase 2 study are likely to be viewed favorably by investors and could lead to increased investor confidence in Lipocine Inc. Meeting both primary and hepatic encephalopathy endpoints demonstrates the potential efficacy of LPCN 1148 in treating cirrhosis, which could significantly impact the company's valuation and future revenue prospects. This news is directly related to Lipocine's core business and product pipeline, making it highly relevant and important to investors.